Natural or Synthetic Therapeutics That Block PAKs

PAKs, RAC/CDC42 (p21)-activated Kinases

Volumn , Issue , 2013, Pages 53-76

  Maruta, Hiroshi ^a   Messerli, Shanta M ^b   Jha, Ramesh K ^c  

^a NF TSC Cure Organisation   (Australia)

^b MARINE BIOLOGICAL LABORATORY   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882571121     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-407198-8.00003-5     Document Type: Chapter

References (102)

1. Maruta H, Burgess AW Regulation of the Ras signalling network. Bioessays 1994, 16:489-496.
2. Tang Y, Chen Z, Ambrose D, Liu J, et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 1997, 17:4454-4464.
3. Manser E, Loo T, Koh C, Zhao Z, et al. PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. Mol Cell 1998, 1:183-192.
4. Obermeier A, Ahmed S, Manser E, Ye SC, et al. PAK promotes morphological changes by acting upstream of Rac. EMBO J 1998, 17:4328-4339.
5. Nur-E-Kamal MSA, Kamal JM, Quresh MM, Maruta H The CDC42-specific inhibitor derived from ACK blocks the v-Ha-RAS-induced transformation. Oncogene 1999, 18:7787-7793.
6. He H, Hirokawa Y, Manser E, Lim L, et al. Signal therapy for RAS induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J 2001, 7:191-202.
7. Zhao L, Ma QL, Calon F, Harris-White M, et al. Role of PAK pathway defects in the cognitive deficits of Alzheimer's disease. Nat Neurosci 2006, 9:234-242.
8. Viaud J, Peterson J An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 2009, 8:2559-2565.
9. Maroney A, Glicksman M, Basma A, Walton K, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 1998, 18:104-111.
10. Nheu T, He H, Hirokawa Y, Tamaki K, et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J 2002, 8:328-336.
11. Lei M, Lu W, Meng W, et al. Structure of PAK1 in an auto-inhibited conformation reveals a multistage activation switch. Cell 2000, 102:387-397.
12. Hirokawa Y, Arnold M, Nakajima H, Zalcberg J, et al. Signal therapy of breast cancer xenograft in mice by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther 2005, 4:956-960.
13. Schupp P, Steube K, Meyer C, et al. Anti-proliferative effects of a new staurosporine derivative isolated from a marine ascidian and its predatory flat worm. Cancer Lett 2001, 174:165-172.
14. Onaka H, Taniguchi S, Igarashi Y, Furumai T Cloning of the staurosporine biosynthetic gene cluster from Streptomyces, sp. TP-ao274 and its heterologous expression in Streptomyces lividans. J Antibiot (Tokyo) 2002, 55:1063-1071.
15. Tipper J, Citron B, Ribeiro P, Kaufmann S Cloning and expression of rabbit and human tryptophan hydroxylase cDNA in E. coli. Arch Biochem Biophys 1994, 315:445-453.
16. He H, Hirokawa Y, Levitzki A, Maruta H An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies. Cancer J 2000, 6:243-248.
17. Wu W, Sun Z, Wu J, Peng X, et al. Trihydrophobin 1 phosphorylation by c-Src regulates MAPK/ERK signaling and cell migration. PLoS One 2012, 7:e29920.
18. He H, Hirokawa Y, Gazit A, Yamashita Y, et al. The Tyr kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Cancer Biol Ther 2004, 3:96-101.
19. Hirokawa Y, Levitzki A, Lessene G, Baell J, et al. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr kinase inhibitors). Cancer Lett 2007, 245:242-251.
20. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999, 3:639-648.
21. Yadav V, Denning MF Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog 2011, 50:346-352.
22. Murray B, Guo CX, Piraino J, Westwick J, et al. Small-molecule PAK inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Cad Sci USA 2010, 107:9446-9451.
23. Qu J, Li X, Novitch B, Zheng Y, et al. PAK4 kinase is essential for embryonic viability and for proper neuronal development. Mol Cell Biol 2003, 23:7122-7133.
24. Ueda H, Nakajima H, Hori Y, Fujita T, et al. FK228, a novel antitumor bicyclic depsipeptide, I. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor activity. J Antibiot 1994, 47:301-310.
25. Nakajima H, Kim YB, Terano H, Yoshida M, et al. FK228, a potent anti-tumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998, 241:126-133.
26. Kobayashi Y, Ohtsuki M, Murakami T, Kobayashi T, et al. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene 2006, 25:512-524.
27. Kodani M, Igishi T, Matsumoto S, Chikumi H, et al. Suppression of PI 3-kinase/AKT signaling pathway is a determinant of the sensitivity to a novel HDAC inhibitor, FK228, in lung adenocarcinoma cells. Oncol Rep 2005, 13:477-483.
28. Campas-Moya C Romidepsin (FK228) for the treatment of CTCL. Drugs Today 2009, 45:787.
29. Tang Y, Marwaha S, Rutkowski J, Tennekoon G, et al. A role for Pak protein kinases in Schwann cell transformation. Proc Natl Acad Sci USA 1998, 95:5139-5144.
30. Hirokawa Y, Tikoo A, Huynh J, Utermark T, et al. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 2004, 10:20-26.
31. Nur-E-Kmal MSA, Varga M, Maruta H The GTPase-activating NF1 fragment of 91 amino acids reverses the v-Ha-RAS-induced malignant phenotype. J Biol Chem 1993, 268:22331-22337.
32. Tikoo A, Varga M, Ramesh V, Gusella J, et al. An anti-RAS function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 1994, 269:23387-23390.
33. Kiosses W, Hood J, Yang S, Gerritsen M, et al. A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res 2002, 90:697-702.
34. Allen J, Jaffer Z, Park S, Burgin S, et al. PAK1 regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics. Blood 2009, 113:2695-2705.
35. Yoshioka K, Foletta V, Bernard O, Itoh K A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 2003, 100:7247-7252.
36. Grunberger D, Banerjee R, Eisinger K, Oltz E, et al. Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis. Experientia 1988, 44:230-232.
37. Matsuno T, Jung SK, Matsumoto Y, Saito M, et al. Preferential cytotoxicity to tumor cells of artepillin C isolated from propolis. Anticancer Res 1997, 17:3565-3568.
38. Awale S, Li F, Onozuka H, Esumi H, et al. Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition. Bioorg Med Chem 2008, 16:181-189.
39. Xu JW, Ikeda K, Kobayakawa A, Ikami T, et al. Down-regulation of Rac1 activation by caffeic acid in aortic smooth muscle cells. Life Sci 2005, 76:2861-2872.
40. Messerli S, Ahn MR, Kunimasa K, Yanagihara M, et al. Artepillin C (ARC) in Brazilian green propolis selectively blocks the oncogenic PAK1 signaling and suppresses the growth of NF tumors in mice. Phytother Res 2009, 23:423-427.
41. Maruta H An innovated approach to in vivo screening for the major anti-cancer drugs. Horizons in cancer research 2010, 41. Nova Science Publishers, pp. 249-59.
42. Demestre M, Messerli S, Celli N, Shahhossini M, et al. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice. Phytother Res 2009, 23:226-230.
43. Sicard A, Semblat JP, Doerig C, Hamelin R, et al. Activation of PAK-MEK signaling pathway in malaria parasite-infected erythrocytes. Cell Microbiol 2011, 13:836-845.
44. Wang JX, Tang W, Shi LP, Wan J, et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Brit J Pharmacol 2007, 150:652-661.
45. Du JH, Zhang HD, Ma ZJ, Ji KM Artesunate induces oncosis-like cell death in vitro and has anti-tumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 2010, 65:895-902.
46. Trager W, Polonsky J The antimalaria activity of Quassinoids against chloroquine-resistant P. falciparum in vitro. Am J Trop Med Hyg 1981, 30:531-537.
47. Ghosh P, Larrahond J, LeQuesne P, Raffauf R Antitumor plants. IV. Constituents of S. versicolor. Lloydia 1977, 40:364-369.
48. Valeriote F, Corbett T, Grieco P, Moher E, et al. Anticancer activity of glaucarubinone analogues. Oncol Res 1998, 10:201-208.
49. Beutler J, Kang MI, Robert F, Clement J, et al. Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition. J Nat Prod 2009, 72:503-506.
50. Adam L, Vadlamudi R, Mandal M, Chernoff J, et al. Regulation of microfilament organization and invasiveness of breast cancer cells by kinase dead PAK1. J Biol Chem 2000, 275:12041-12050.
51. Mendora-Gamboa E, Siwak D, Tari A The HER2/Grb2/Akt pathway regulates DNA binding activity of AP-1 in breast cancer cells. Oncol Rep 2004, 12:904-908.
52. Zarse K, Bossecker A, Mueller-Kuhrt L, Siems K, et al. The phytochemical glaucarubinone promotes mitochondrial metabolism, reduces body fat and extends the life span of C. elegans. Horm Metab Res 2011, 43:241-243.
53. Castelletti D, Fiaschetti G, Di Dato V, Ziegler U, et al. The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors. Mol Cancer Ther 2010, 9:3145-3157.
54. Yang SH, Wang X, Contino G, Leasa M, et al. Pancreatic cancers require autophagy for their growth. Gene Develop 2011, 25:717-729.
55. Hirokawa Y, Nheu T, Grimm K, Mautner V, et al. Sichuan pepper extracts block the PAK1/cyclin D1 pathway and the growth of NF1-deficient cancer xenograft in mice. Cancer Biol Ther 2006, 5:305-309.
56. Cai XZ, Wang J, Li XD, Wang GL, et al. Curcumin suppresses proliferation and invasion in human gastric cancer cells by down-regulation of PAK1 activity and cyclin D1 expression. Cancer Biol Ther 2009, 8:1360-1368.
57. Lee ES, Uhm KO, Lee YM, Han M, et al. CAPE stimulates glucose uptake through AMPK activation in skeletal muscle cells. Biochem Biophys Res Commun 2007, 361:854-858.
58. Pan W, Yang C, Cao C, Song X, et al. AMPK mediates curcumin-induced cell death of CaOV3 ovarian cancer cells. Oncol Rep 2008, 20:1553-1559.
59. Li L, Braiteh FS, Kurzrock R Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104:1322-1331.
60. Mach C, Mathew L, Mosley S, Kurzrock R, et al. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res 2009, 29:1895-1899.
61. Yadav V, Suresh S, Devi K, Yadav S Effect of cyclodextrin complexation of curcumin on its solubility and anti-angiogenic and anti-inflammatory activity in Rat colitis model. AAPS Pharm Sci Tech 2009, 10:752-762.
62. Zhang L, Lao YK, Xia W, Hortbagyi G, et al. Tyr kinase inhibitor emodin suppresses the growth ErbB2-overexpressing breast cancer cells in athymic mice. Clin Cancer Res 1999, 5:343-353.
63. Xue J, Ding W, Liu Y Anti-diabetic effects of emodin involved in the activation of PPARgamma in high-fat diet-fed and low dose of streptozotocin-induced diabetic mice. Fitoterapia 2010, 81:173-177.
64. Chang KS, Gao C, Wang LC Berberine-induced morphologic differentiation and down-regulation of c-Ki-ras2 protooncogene expression in human teratocarcinoma cells. Cancer Lett 1990, 55:103-108.
65. Brusq JM, Ancellin N, Grondin P, Guillard R, et al. Inhibition of lipid synthesis through activation of AMPK: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006, 47:1281-1288.
66. Tsang CM, Lau EP, Di K, Cheung PY, et al. Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int J Mol Med 2009, 24:131-138.
67. Bahar M, Deng Y, Zhu XH, He SS, et al. Potent anti-protozoan activity of a novel semi-synthetic berberine derivative. Bioorg Med Chem Lett 2011, 21:2606-2610.
68. Omura S, Crump A The life and times of ivermectin: a success story. Nat Rev Microbiol 2004, 2:894-899.
69. Hashimoto H, Messerli S, Sudo T, Maruta H Ivermectin inactivates the kinase PAK1 and block the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther 2009, 3:243-246.
70. Drinyaev V, Mosin V, Kluglyak E, Novik.T, et al. Antitumor effect of avermectin. Eur J Pharmacol 2004, 501:19-23.
71. Li HB, Ge YK, Zheng XX, Zhang L Salidroside stimulated glucose uptake in skeletal muscle cells by activating AMPK. Eur J Pharmacol 2008, 588:165-169.
72. Wiegant F, Surinova S, Ytsma E, Langelaar-Makkinje M, et al. Plant adaptogens increase lifespan and stress resistance in C. elegans. Biogerontology 2009, 10:27-42.
73. Skopin'ska-Rozewska E, Malinowski M, Wasiutyn'ski A, Sommer E, et al. The influence of Rhodiola quadrifida 50% hydro-alcoholic extract and salidroside on tumor-induced angiogenesis in mice. Pol J Vet Sci 2008, 11:97-104.
74. Tsuda S, Egawa T, Ma X, Oshima R, et al. Coffee polyphenol caffeic acid but not chlorogenic acid increases AMPK and insulin-independent glucose transport in rat skeletal muscle. J Nutr Biochem 2012, 23:1403-1409.
75. Waite KA, Sinden MR, Eng C Phytoestrogen exposure elevates PTEN levels. Hum Mol Genet 2005, 14:1457-1463.
76. Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik G, et al. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med 2008, 12:2350-2361.
77. Deguchi A, Miyashi H, Kojima Y, Okawa K, et al. LKB1 inactivates PAK1 by phosphorylation of Thr 109 in the p21-binding domain. J Biol Chem 2010, 285:18283-18290.
78. Zhou GC, Meyers R, Li Y, Chen Y, et al. Role of AMPK in mechanism of metformin. J Clin Invest 2001, 108:1167-1174.
79. Huang Q, Shen HM, Ong CN Emodin inhibits tumor cell migration through suppression of the PI-3 kinase/CDC42/Rac pathway. Cell Mol Life Sci 2005, 62:1167-1175.
80. Shin DH, Kim OK, Jun HS, Kang MK Inhibitory effect of capsaicin on B16-F10 melanoma cell migration via the PI-3 kinase/Akt/Rac1 signal pathway. Exp Mol Med 2008, 40:486-494.
81. Hwang JT, Park IJ, Shin JI, Lee YK, et al. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMPK. Biochem Biophys Res Commun 2005, 338:694-699.
82. Way TD, Kao MC, Lin JK Apigenin induces apoptosis through proteosomal degradation of ErBB2 in ErBB2-overexpressing breast cancer cells via the PI3-kinase/AKT-dependent pathway. J Biol Chem 2004, 279:4479-4489.
83. Zang M, Xu S, Maitland-Toolan K, Zuccollo A, et al. Polyphenols stimulate AMPK, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDLR-deficient mice. Diabetes 2006, 55:2180-2191.
84. Khanal P, Kang BS, Yun HJ, Cho HG, et al. Aglycon of rhizochalin from the Rhizochalina incrustata induces apoptosis via activation of AMPK in HT-29 colon cancer cells. Biol Pharm Bull 2011, 34:1553-1559.
85. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 2003, 278:35501-35507.
86. Harada S, Kishimoto M, Kobayashi M, Nakamoto K, et al. Honokiol suppresses the development of post-ischemic glucose intolerance and neuronal damage in mice. J Nat Med 2012, 66:591-599.
87. Porchia L, Guerra M, Wang YC, Zhang YL, et al. OSU-03012, a celecoxib derivative, directly targets PAK. Mol Pharmacol 2007, 72:1124-1131.
88. Bai LY, Weng JR, Tsai CH, Sargeant A, et al. OSU-03012 sensitizes TIB-196 myeloma cells to imanitib mesylate via AMPK and STAT3 pathways. Leuk Res 2010, 34:826-830.
89. Spector N, Yarden Y, Smith B, Lyass L, et al. Activation of AMPK by ErbB2/ErbB1 Tyr kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA 2007, 104:10607-10612.
90. Sullivan J, Brocklehurst K, Marley A, Carey K, et al. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMPK. FEBBS Lett 1994, 353:33-36.
91. Sun Y, Connors K, Yang DQ AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol Cell Biochem 2007, 306:239-245.
92. Shaw R, Kosmatka S, Bardeesy N, Hurley R, et al. The tumor suppressor LKB1 kinase directly activates AMPK and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004, 101:3329-3335.
93. Kenyon C, Chang J, Gensch E, Rudner A, et al. A C. elegans mutant that lives twice as long as wild type. Nature 1993, 366:461-464.
94. Greer E, Dowlatshahi D, Banko M, Villen J, et al. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr Biol 2007, 17:1646-1656.
95. Vadlamudi R, Kumar R p21-Activated kinase 1 (PAK1): an emerging therapeutic target. Cancer Treat Res 2004, 119:77-88.
96. Lee KS, Lee BS, Semnani S, Avanesian A, et al. Curcumin extends life span, improves health span, and modulates the expression of age-associated aging genes in D. melanogaster. Rejuven Res 2010, 13:561-570.
97. Pietsch K, Saul N, Shumon Chakrabarti S, Stürzenbaum S, et al. Hormetins, antioxidants and prooxidants: defining quercetin-, caffeic acid- and rosmarinic acid-mediated life extension in C. elegans. Biogerontology 2011, 12:329-347.
98. Walker G, White T, McColl G, Jenkins N, et al. Heat shock protein accumulation is upregulated in a long-lived mutant of C. elegans. J Gerontol A Biol Sci Med Sci 2001, 56:B281-B287.
99. Engelberg D, Zandi E, Parker C, Karin M The yeast and mammalian RAS pathways control transcription of heat shock genes independently of heat shock transcription factor. Mol Cell Biol 1994, 14:4929-4937.
100. Goldman R, Levy R, Peles E, Yarden Y The heterodimerization of the ErbB1 and ErbB2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 1990, 29:11024-11028.
101. Fedrov S, Makarieva T, Guzii A, Shubina L, et al. Marine two-headed sphingolipid-like compound rhizochalin inhibits EGF-induced transformation of JB6 P+ Cl41 cells. Lipids 2009, 44:777-785.
102. Bokoch G, Reilly A, Daniels H, King C, et al. A GTPase-independent mechanism of PAK1 activation. Regulation by sphingosine and other biologically active lipids. J Biol Chem 1998, 273:8137-8144.